Does the media prefer JAZZ or MANE?

In the previous week, Jazz Pharmaceuticals had 16 more articles in the media than Veradermics. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 2 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Jazz Pharmaceuticals' score of -0.01 indicating that Veradermics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Jazz Pharmaceuticals 7 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor MANE or NBIX?

In the previous week, Neurocrine Biosciences had 19 more articles in the media than Veradermics. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 2 mentions for Veradermics. Neurocrine Biosciences' average media sentiment score of 1.28 beat Veradermics' score of 0.66 indicating that Neurocrine Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Neurocrine Biosciences 17 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to CORT or MANE?

In the previous week, Corcept Therapeutics had 17 more articles in the media than Veradermics. MarketBeat recorded 19 mentions for Corcept Therapeutics and 2 mentions for Veradermics. Corcept Therapeutics' average media sentiment score of 0.90 beat Veradermics' score of 0.66 indicating that Corcept Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Corcept Therapeutics 14 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ELAN or MANE?

In the previous week, Elanco Animal Health had 16 more articles in the media than Veradermics. MarketBeat recorded 18 mentions for Elanco Animal Health and 2 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 1.37 beat Veradermics' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 17 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer AXSM or MANE?

In the previous week, Axsome Therapeutics had 18 more articles in the media than Veradermics. MarketBeat recorded 20 mentions for Axsome Therapeutics and 2 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 0.84 beat Veradermics' score of 0.66 indicating that Axsome Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 10 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veradermics (MANE) Competitors

$97.71 -0.75 (-0.76%)

As of 03:12 PM Eastern

Compare

MANE vs. JAZZ, NBIX, CORT, ELAN, and AXSM

Should you buy Veradermics stock or one of its competitors? Veradermics's main competitors and comparable companies include Jazz Pharmaceuticals (JAZZ), Neurocrine Biosciences (NBIX), Corcept Therapeutics (CORT), Elanco Animal Health (ELAN), and Axsome Therapeutics (AXSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Veradermics compare to Jazz Pharmaceuticals?

Jazz Pharmaceuticals (NASDAQ:JAZZ) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, institutional ownership, dividends, valuation, media sentiment, analyst recommendations, earnings and risk.

Jazz Pharmaceuticals has a net margin of 20.45% compared to Veradermics' net margin of 0.00%. Jazz Pharmaceuticals' return on equity of 33.97% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jazz Pharmaceuticals	20.45%	33.97%	13.02%
Veradermics	N/A	N/A	N/A

Jazz Pharmaceuticals currently has a consensus target price of $285.44, indicating a potential upside of 15.23%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 55.95%. Given Veradermics' higher possible upside, analysts clearly believe Veradermics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jazz Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	16 Buy rating(s)	1 Strong Buy rating(s)	3.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

89.1% of Jazz Pharmaceuticals shares are owned by institutional investors. 4.1% of Jazz Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Veradermics has lower revenue, but higher earnings than Jazz Pharmaceuticals. Veradermics is trading at a lower price-to-earnings ratio than Jazz Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jazz Pharmaceuticals	$4.60B	3.49	-$356.15M	$14.50	17.08
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

In the previous week, Jazz Pharmaceuticals had 16 more articles in the media than Veradermics. MarketBeat recorded 18 mentions for Jazz Pharmaceuticals and 2 mentions for Veradermics. Veradermics' average media sentiment score of 0.66 beat Jazz Pharmaceuticals' score of -0.01 indicating that Veradermics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Jazz Pharmaceuticals	7 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Jazz Pharmaceuticals beats Veradermics on 12 of the 15 factors compared between the two stocks.

How does Veradermics compare to Neurocrine Biosciences?

Veradermics (NYSE:MANE) and Neurocrine Biosciences (NASDAQ:NBIX) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, institutional ownership, media sentiment, profitability and earnings.

92.6% of Neurocrine Biosciences shares are held by institutional investors. 4.6% of Neurocrine Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Neurocrine Biosciences has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Neurocrine Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	-$70M	-$1.90	N/A
Neurocrine Biosciences	$3.37B	4.77	$478.60M	$6.82	23.21

Veradermics currently has a consensus price target of $153.00, indicating a potential upside of 55.95%. Neurocrine Biosciences has a consensus price target of $201.05, indicating a potential upside of 27.03%. Given Veradermics' higher probable upside, equities analysts plainly believe Veradermics is more favorable than Neurocrine Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Neurocrine Biosciences	0 Sell rating(s)	4 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Neurocrine Biosciences had 19 more articles in the media than Veradermics. MarketBeat recorded 21 mentions for Neurocrine Biosciences and 2 mentions for Veradermics. Neurocrine Biosciences' average media sentiment score of 1.28 beat Veradermics' score of 0.66 indicating that Neurocrine Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Neurocrine Biosciences	17 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurocrine Biosciences has a net margin of 20.91% compared to Veradermics' net margin of 0.00%. Neurocrine Biosciences' return on equity of 22.43% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Neurocrine Biosciences	20.91%	22.43%	15.64%

Summary

Neurocrine Biosciences beats Veradermics on 14 of the 15 factors compared between the two stocks.

How does Veradermics compare to Corcept Therapeutics?

Corcept Therapeutics (NASDAQ:CORT) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, risk, valuation, media sentiment, analyst recommendations, dividends and earnings.

Corcept Therapeutics currently has a consensus target price of $138.17, indicating a potential upside of 21.48%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 55.95%. Given Veradermics' stronger consensus rating and higher possible upside, analysts plainly believe Veradermics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Corcept Therapeutics has higher revenue and earnings than Veradermics. Veradermics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	16.15	$99.65M	$0.42	270.81
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

In the previous week, Corcept Therapeutics had 17 more articles in the media than Veradermics. MarketBeat recorded 19 mentions for Corcept Therapeutics and 2 mentions for Veradermics. Corcept Therapeutics' average media sentiment score of 0.90 beat Veradermics' score of 0.66 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	14 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.6% of Corcept Therapeutics shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics has a net margin of 6.52% compared to Veradermics' net margin of 0.00%. Corcept Therapeutics' return on equity of 8.26% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.52%	8.26%	6.45%
Veradermics	N/A	N/A	N/A

Summary

Corcept Therapeutics beats Veradermics on 11 of the 14 factors compared between the two stocks.

How does Veradermics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their risk, profitability, earnings, institutional ownership, analyst recommendations, valuation, dividends and media sentiment.

Veradermics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -3.96%. Elanco Animal Health's return on equity of 8.13% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-3.96%	8.13%	3.99%
Veradermics	N/A	N/A	N/A

Veradermics has lower revenue, but higher earnings than Elanco Animal Health. Elanco Animal Health is trading at a lower price-to-earnings ratio than Veradermics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.58	-$232M	-$0.41	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Elanco Animal Health presently has a consensus price target of $29.09, indicating a potential upside of 19.62%. Veradermics has a consensus price target of $153.00, indicating a potential upside of 55.95%. Given Veradermics' higher probable upside, analysts plainly believe Veradermics is more favorable than Elanco Animal Health.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Elanco Animal Health had 16 more articles in the media than Veradermics. MarketBeat recorded 18 mentions for Elanco Animal Health and 2 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 1.37 beat Veradermics' score of 0.66 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	17 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Veradermics on 11 of the 15 factors compared between the two stocks.

How does Veradermics compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Veradermics (NYSE:MANE) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their risk, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and valuation.

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Axsome Therapeutics had 18 more articles in the media than Veradermics. MarketBeat recorded 20 mentions for Axsome Therapeutics and 2 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 0.84 beat Veradermics' score of 0.66 indicating that Axsome Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	10 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -24.68%. Veradermics' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Veradermics	N/A	N/A	N/A

Veradermics has lower revenue, but higher earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Veradermics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	17.12	-$183.17M	-$3.75	N/A
Veradermics	N/A	N/A	-$70M	-$1.90	N/A

Axsome Therapeutics currently has a consensus target price of $267.60, indicating a potential upside of 28.21%. Veradermics has a consensus target price of $153.00, indicating a potential upside of 55.95%. Given Veradermics' higher probable upside, analysts clearly believe Veradermics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	2 Strong Buy rating(s)	2.91
Veradermics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

Summary

Axsome Therapeutics beats Veradermics on 8 of the 15 factors compared between the two stocks.

Get Veradermics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	Veradermics	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$4.10B	$12.30B	$7.25B	$23.61B
Dividend Yield	N/A	2.60%	2.53%	3.75%
P/E Ratio	-51.64	789.77	273.84	29.39
Price / Sales	N/A	956.14	675.54	16.84
Price / Cash	N/A	92.66	76.98	31.92
Price / Book	5.04	12.42	12.90	7.62
Net Income	-$70M	$2.83B	$3.48B	$1.07B
7 Day Performance	-3.51%	2.26%	-0.42%	-0.50%
1 Month Performance	-2.83%	5.06%	6.41%	0.74%
1 Year Performance	N/A	9.28%	24.92%	13.96%

Veradermics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE Veradermics	2.6271 of 5 stars	$97.71 -0.8%	$153.00 +56.6%	N/A	$4.08B	N/A	N/A	19
JAZZ Jazz Pharmaceuticals	4.0395 of 5 stars	$250.55 +0.5%	$279.00 +11.4%	+89.4%	$16.26B	$4.27B	17.27	2,890	Insider Trade High Trading Volume
NBIX Neurocrine Biosciences	4.9352 of 5 stars	$155.77 -0.5%	$200.86 +28.9%	+11.2%	$15.84B	$2.86B	22.85	2,000	Positive News Analyst Forecast
CORT Corcept Therapeutics	4.1812 of 5 stars	$118.35 -1.2%	$138.17 +16.7%	+54.7%	$12.80B	$761.41M	281.92	300
ELAN Elanco Animal Health	4.6816 of 5 stars	$24.66 -1.7%	$29.09 +18.0%	+37.6%	$12.31B	$5.02B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 9/3/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradermics (MANE) Competitors

MANE vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Veradermics compare to Jazz Pharmaceuticals?

Summary

How does Veradermics compare to Neurocrine Biosciences?

Summary

How does Veradermics compare to Corcept Therapeutics?

Summary

How does Veradermics compare to Elanco Animal Health?

Summary

How does Veradermics compare to Axsome Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradermics (MANE) Competitors

MANE vs. JAZZ, NBIX, CORT, ELAN, and AXSM

How does Veradermics compare to Jazz Pharmaceuticals?

Is JAZZ or MANE more profitable?

Do analysts rate JAZZ or MANE?

Do insiders & institutionals believe in JAZZ or MANE?

Which has stronger earnings and valuation, JAZZ or MANE?

Does the media prefer JAZZ or MANE?

Summary

How does Veradermics compare to Neurocrine Biosciences?

Do institutionals and insiders hold more shares of MANE or NBIX?

Which has higher valuation & earnings, MANE or NBIX?

Do analysts recommend MANE or NBIX?

Does the media favor MANE or NBIX?

Is MANE or NBIX more profitable?

Summary

How does Veradermics compare to Corcept Therapeutics?

Do analysts recommend CORT or MANE?

Which has stronger valuation and earnings, CORT or MANE?

Does the media refer more to CORT or MANE?

Do insiders and institutionals believe in CORT or MANE?

Is CORT or MANE more profitable?

Summary

How does Veradermics compare to Elanco Animal Health?

Is ELAN or MANE more profitable?

Which has better earnings and valuation, ELAN or MANE?

Do insiders & institutionals believe in ELAN or MANE?

Do analysts rate ELAN or MANE?

Does the media favor ELAN or MANE?

Summary

How does Veradermics compare to Axsome Therapeutics?

Do institutionals and insiders believe in AXSM or MANE?

Does the media prefer AXSM or MANE?

Is AXSM or MANE more profitable?

Which has higher valuation and earnings, AXSM or MANE?

Do analysts rate AXSM or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools